logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
24/12/2025
Citius Pharma (CTXR.US): The Q4 revenue report for 2025 showed a revenue of $0, same as the previous value, with an expected value of $5.756 million; earnings per share were -$0.11, compared to the previous value of -$1.72, and an expected value of -$0.24.
Latest
3 m ago
Nikkei Index futures opened at 50,510 points on the Singapore Exchange, up 0.1%.
4 m ago
Zai Ding Pharmaceuticals' Ketrozole has been approved for the treatment of schizophrenia in China.
4 m ago
New Stock News | Frontera Therapeutics Files for Listing on Hong Kong Stock Exchange, Dedicated to Developing Innovative Recombinant Adeno-Associated Virus (rAAV) Gene Therapy Independently.
4 m ago
JCR Pharmaceuticals Co., Ltd.: Italian pharmaceutical company and JCR Pharmaceuticals announced an agreement on the commercialization of Givinostat in Japan, and strategic cooperation in the field of rare diseases.
5 m ago
"Spring fever" market expectations are heating up, securities firms pulse the two major investment themes.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.